Peter Steinberger
Overview
Explore the profile of Peter Steinberger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
128
Citations
2601
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Meyer M, Parpoulas C, Barthelemy T, Becker J, Charoentong P, Lyu Y, et al.
Front Immunol
. 2024 Jan;
14:1294565.
PMID: 38239352
Peptide-loaded MHC class I (pMHC-I) multimers have revolutionized our capabilities to monitor disease-associated T cell responses with high sensitivity and specificity. To improve the discovery of T cell receptors (TCR)...
22.
Sharma S, Whitehead T, Kotowski M, Ng E, Clarke J, Leitner J, et al.
Life Sci Alliance
. 2023 Dec;
7(3).
PMID: 38073578
The recent success of immunotherapies relying on manipulation of T-cell activation highlights the value of characterising the mediators of immune checkpoint signaling. CRISPR/Cas9 is a popular approach for interrogating signaling...
23.
Izadi S, Gumpelmair S, Coelho P, Duarte H, Gomes J, Leitner J, et al.
Plant Biotechnol J
. 2023 Dec;
22(5):1224-1237.
PMID: 38050338
Immune checkpoint blocking therapy targeting the PD-1/PD-L1 inhibitory signalling pathway has produced encouraging results in the treatment of a variety of cancers. Durvalumab (Imfinzi) targeting PD-L1 is currently used for...
24.
Funk M, Leitner J, Gerner M, Hammerler J, Salzer B, Lehner M, et al.
Nat Commun
. 2023 Nov;
14(1):7804.
PMID: 38016944
Interactions of membrane-resident proteins are important targets for therapeutic interventions but most methods to study them are either costly, laborious or fail to reflect the physiologic interaction of membrane resident...
25.
Aigner-Radakovics K, de Sousa Linhares A, Salzer B, Lehner M, Izadi S, Castilho A, et al.
Sci Signal
. 2023 Oct;
16(805):eadg2610.
PMID: 37788323
Lymphocyte activation gene 3 (LAG3) is an inhibitory immune checkpoint receptor that restrains autoimmune and antitumor responses, but its evolutionarily conserved cytoplasmic tail lacks classical inhibitory motifs. Major histocompatibility complex...
26.
Leitner J, Egerer R, Waidhofer-Sollner P, Grabmeier-Pfistershammer K, Steinberger P
Front Immunol
. 2023 Aug;
14:1208631.
PMID: 37575254
Introduction: Targeting costimulatory receptors of the tumor necrosis factor receptor (TNFR) superfamily with agonistic antibodies is a promising approach in cancer immuno therapy. It is known that their efficacy strongly...
27.
Schwertner K, Gelles K, Leitner J, Steinberger P, Gundacker C, Vrticka R, et al.
Heliyon
. 2023 Aug;
9(8):e18247.
PMID: 37533998
The receptor for advanced glycation end products (RAGE) is encoded by , a gene that is subjected to tissue-specific alternative splicing. Splice variants of RAGE in intestine and placenta are...
28.
Kuncewicz K, Bojko M, Battin C, Karczynska A, Sieradzan A, Sikorska E, et al.
Biomed Pharmacother
. 2023 Jul;
165:115161.
PMID: 37473684
Immune checkpoints can be divided into co-stimulatory and co-inhibitory molecules that regulate the activation and effector functions of T cells. The co-inhibitory pathways mediated by ICPs are used by cancer...
29.
Battin C, de Sousa Linhares A, Leitner J, Grossmann A, Lupinek D, Izadi S, et al.
Cancer Immunol Immunother
. 2023 Jun;
72(9):3029-3043.
PMID: 37310433
Targeting co-stimulatory receptors promotes the activation and effector functions of anti-tumor lymphocytes. 4-1BB (CD137/TNFSF9), a member of the tumor necrosis factor receptor superfamily (TNFR-SF), is a potent co-stimulatory receptor that...
30.
Tauber P, Kratzer B, Schatzlmaier P, Smole U, Kohler C, Rausch L, et al.
Front Immunol
. 2023 Apr;
14:1094694.
PMID: 37090735
Background: Treg cells have been shown to be an important part of immune-homeostasis and IL-2 which is produced upon T cell receptor (TCR)-dependent activation of T lymphocytes has been demonstrated...